1. Home
  2. NMZ vs MPLT Comparison

NMZ vs MPLT Comparison

Compare NMZ & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

NMZ

Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

HOLD

Current Price

$10.34

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$37.44

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMZ
MPLT
Founded
2003
2018
Country
United States
United States
Employees
N/A
133
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NMZ
MPLT
Price
$10.34
$37.44
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
584.0K
536.2K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
5.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.83
$12.24
52 Week High
$10.77
$40.43

Technical Indicators

Market Signals
Indicator
NMZ
MPLT
Relative Strength Index (RSI) 44.84 58.18
Support Level $10.25 $26.20
Resistance Level $10.43 $40.43
Average True Range (ATR) 0.06 2.87
MACD -0.03 -0.22
Stochastic Oscillator 8.93 54.38

Price Performance

Historical Comparison
NMZ
MPLT

About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: